Enlivex Therapeutics (NASDAQ:ENLV) Downgraded to Sell Rating by Wall Street Zen

Enlivex Therapeutics (NASDAQ:ENLV) was downgraded by research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a note issued to investors on Saturday.

Several other analysts have also issued reports on the stock. HC Wainwright boosted their target price on shares of Enlivex Therapeutics from $7.00 to $13.00 and gave the company a “buy” rating in a research report on Monday, January 12th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Enlivex Therapeutics in a research report on Monday, December 29th. One equities research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $13.00.

Enlivex Therapeutics Stock Down 3.7%

NASDAQ ENLV opened at $1.05 on Friday. Enlivex Therapeutics has a 52 week low of $0.66 and a 52 week high of $2.10. The firm has a market capitalization of $249.25 million, a P/E ratio of -1.91 and a beta of 1.55. The company has a 50-day moving average price of $1.10 and a 200-day moving average price of $1.02.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. Jane Street Group LLC grew its stake in shares of Enlivex Therapeutics by 527.4% during the 1st quarter. Jane Street Group LLC now owns 80,759 shares of the company’s stock valued at $78,000 after acquiring an additional 67,886 shares during the period. Citizens Financial Group Inc. RI bought a new stake in Enlivex Therapeutics during the 3rd quarter worth approximately $241,000. Susquehanna International Group LLP bought a new stake in Enlivex Therapeutics during the 3rd quarter worth approximately $57,000. Renaissance Technologies LLC lifted its holdings in Enlivex Therapeutics by 99.4% during the fourth quarter. Renaissance Technologies LLC now owns 313,628 shares of the company’s stock valued at $221,000 after purchasing an additional 156,336 shares in the last quarter. Finally, HRT Financial LP lifted its holdings in Enlivex Therapeutics by 719.4% during the fourth quarter. HRT Financial LP now owns 153,990 shares of the company’s stock valued at $108,000 after purchasing an additional 135,198 shares in the last quarter. Institutional investors own 1.02% of the company’s stock.

About Enlivex Therapeutics

Enlivex Therapeutics is a clinical-stage biopharmaceutical company headquartered in Ness Ziona, Israel, that focuses on developing innovative immunotherapies for life-threatening inflammatory conditions. Founded in 2015, the company trades on the NASDAQ under the symbol ENLV and leverages a proprietary cell-based platform to restore immune balance in critical care settings.

The company’s lead product candidate, Allocetra, comprises reprogrammed apoptotic cell therapy designed to recalibrate the innate immune system.